Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uproleselan, Fludarabine, and Cytarabine in Relapsed/Refractory AML, MDS, or MPAL
NCT05146739Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of uproleselan in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and mixed phenotype acute leukemia (MPAL), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose or Recommended Phase 2 Dose of Uproleselan at 28 days, Cycle 1 Dose Limiting Toxicity of Uproleselan at 28 days and 4 more. Started Oct 2023; status: active, not recruiting.
02
Drugs
uproleselan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT05146739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05146739.